

---

# When Personalization Harms: Reconsidering the Use of Group Attributes for Prediction

---

Anonymous Author(s)

Affiliation

Address

email

## Abstract

1 Machine learning models often use group attributes to assign personalized predictions. In this work, we show that models that use group attributes can assign  
2 unnecessarily inaccurate predictions to specific groups – i.e., that training a model  
3 with group attributes can reduce performance for specific groups. We propose  
4 formal conditions to ensure the “fair use” of group attributes in prediction models –  
5 i.e., collective preference guarantees that can be checked by training one additional  
6 model. We characterize how machine learning models can exhibit fair use due  
7 to standard practices in specification, training, and deployment. We study the  
8 prevalence of fair use violations in clinical prediction models. Our results highlight  
9 the inability to resolve fair use violations, underscore the need to measure the  
10 gains of personalization for all groups who provide personal data, and illustrate  
11 actionable interventions to mitigate harm.  
12

## 13 1 Introduction

14 Machine learning models are often used to support or automate decisions that affect people. In  
15 medicine, for example, models diagnose illnesses [64, 31, 73], estimate survival rates [78], and  
16 predict treatment response [41]. In such applications, medical decisions follow the ethical principles  
17 of beneficence (“do the best”) and non-maleficence (“do no harm”) [8]. In turn, models that support  
18 medical decisions are designed to perform as well as possible without inflicting harm. These principles  
19 explain why so many clinical prediction models use *group attributes* that encode characteristics like  
20 sex and age – i.e. characteristics that would be prohibited for models in lending or hiring. To predict  
21 as well as possible on a heterogeneous population, models must encode all characteristics that could  
22 tell people apart [47].

23 The prevalence of group attributes in prediction models reflects a need for *personalization*,<sup>1</sup> but  
24 do personalized models that use group attributes improve performance for every group? In this  
25 paper, we refer to this principle as *fair use*. Fair use enshrines the basic promise of personalization in  
26 applications like precision medicine – i.e., that each person who reports personal characteristics should  
27 expect a tailored performance gain in return. In prediction tasks with group attributes, this means  
28 that every group should expect better performance from a *personalized model* that solicits group  
29 membership compared to a *generic model* that does not. These gains should be *tailored*, meaning that  
30 every group should prefer their personalized predictions over the personalized predictions assigned to  
31 another group.

---

<sup>1</sup>Personalization is a term that encompasses a breadth of techniques that use personal data. Here, we use it to describe approaches that target *groups* rather than *individuals* – i.e., “categorization” rather than “individualization” as per the taxonomy of Fan & Poole [27].

GROUP	SIZE	ERROR RATE		GAIN
		$R(h_0)$	$R_g(h_g)$	$\Delta_g(h_g, h_0)$
$g$	$n_g$			
female, <30	48	38.1%	26.8%	11.3%
male, <30	49	23.9%	26.7%	-2.8%
female, 30 to 60	307	30.3%	29.1%	1.2%
male, 30 to 60	307	15.4%	15.2%	0.2%
female, 60+	123	19.3%	21.9%	-2.6%
male, 60+	181	11.0%	8.2%	2.8%
<b>Total</b>	1152	20.4%	19.4%	1.0%

**Figure 1:** Personalization can reduce performance for specific groups. We show the gains of personalization for a classifier to screen for obstructive sleep apnea (i.e., the `apnea` dataset in §4). We fit a personalized model  $h_g$  and generic model  $h_0$  with logistic regression, personalizing  $h_g$  with a one-hot encoding of `sex` and `age_group`. As shown, personalization reduces training error from 20.4% to 19.4% but *increases* training error at for 2 groups: (female, 60+) and (male, <30). These effects are also present on test data.

Machine learning models are trained to use group attributes in ways that improve performance at a population level. In practice, this means that models trained with group attributes assign predictions that are unnecessarily inaccurate to specific groups due to routine decisions in model specification or model selection (see Figure 1). In many real-world applications, this drop in performance reflects harm. In clinical applications, for example, inaccurate predictions undermine medical decisions and health outcomes. This harm is silent and avoidable. Silent because fair use violations would only draw attention if model developers were to evaluate the *gains* of personalization for *intersectional* groups. Avoidable because a fair use violation shows that a group could receive better predictions from a generic model or a personalized model for another group; thus we can always resolve a fair use violation by assigning predictions from this better performing model.

Although many prediction models that use group attributes to assign personalized predictions, there is little awareness that this practice could reduce performance at a group level [see e.g., 2, 63]. Simply put, it is hard to imagine how a model that accounts for group membership can perform worse than a model that does not. Our goal in this paper is to expose this effect and lay the foundations to address it. To this end, we characterize how fair use violations arise, demonstrate their prevalence in real-world applications, and propose interventions to mitigate their harm. Specifically, the main contributions of our work include:

1. We propose formal conditions to ensure the fair use of group attributes in prediction models.
2. We characterize how common approaches to personalization in machine learning can produce personalized models to exhibit fair use violations. These “failure modes” delineate the root causes of fair use violations, and inform interventions that mitigate harm.
3. We conduct a comprehensive study on the gains of personalization in clinical prediction models for decision-making, ranking, and risk assessment. Our results demonstrate the prevalence of fair use violations across model classes and personalization techniques, and highlight the challenges of resolving these violations through changes to model development.
4. We present a case study on personalization for a model trained to predict mortality for patients with acute kidney injury. Our study shows how a fair use audit can safeguard against “race correction” in clinical prediction models, and facilitate targeted interventions that reduce harm (Appendix F).

## 2 Fair Use Guarantees

In this section, we present formal conditions for the fair use of group attributes in prediction. We provide notation and preliminaries for this section in Appendix A.

### 2.1 Fair Use

We start with Definition 1, which characterizes the fair use of a group attribute in terms of collective preference guarantees.

66 **Definition 1** (Fair Use). A personalized model  $h : \mathcal{X} \times \mathcal{G} \rightarrow \mathcal{Y}$  guarantees the fair use of a group  
67 attribute  $\mathcal{G}$  if

$$\Delta_{\mathbf{g}}(h_{\mathbf{g}}, h_0) \geq 0 \quad \text{for all groups } \mathbf{g} \in \mathcal{G}, \quad (1)$$

$$\Delta_{\mathbf{g}}(h_{\mathbf{g}}, h_{\mathbf{g}'}) \geq 0 \quad \text{for all groups } \mathbf{g}, \mathbf{g}' \in \mathcal{G} \quad (2)$$

68 Condition (1) captures *rationality* for group  $\mathbf{g}$ : a majority of group  $\mathbf{g}$  prefers a personalized model  
69  $h_{\mathbf{g}}$  to a generic model  $h_0$ . Condition (2) captures *envy-freeness* for group  $\mathbf{g}$ : a majority of group  $\mathbf{g}$   
70 prefers their predictions to predictions personalized for any other group. These conditions enshrine  
71 minimal expectations of groups from a personalized model. Without rationality, a majority in some  
72 group would prefer the generic model. Without envy-freeness, a majority in some group would prefer  
73 the personalized predictions assigned to another group.

74 The fair use conditions in Definition 1 are collective, in that performance is measured over individuals  
75 in a group; and weak, in that the expected performance gain is non-negative – i.e., no group will  
76 be harmed. The conditions can be adapted to different prediction tasks by choosing a suitable risk  
77 metric. Since fair use conditions represent guarantees on the expected gains of personalization, a  
78 suitable metric should measure model performance exactly (c.f. a surrogate metric that we optimize  
79 to fit a model (see Figure 5 in Section 3). In classification tasks where we want accurate decisions,  
80 this would be the error rate. In tasks where we want reliable risk estimates, it would be the expected  
81 calibration error [54].

82 Personalized models that obey fair use guarantees incentivize groups to truthfully report group  
83 membership in deployment [see e.g., 39, 62, 30]. ]

## 84 2.2 Use Cases

85 Relevant use cases for fair use guarantees include:

86 *Protected Classes*: Models sometimes include group attributes that encode immutable characteristics  
87 due to application-specific norms or special provisions [see 44, 45]. For example, `sex` is a protected  
88 characteristic in employment law, but not in medicine [see e.g., 56, for a discussion on the use of sex to  
89 predict cardiovascular disease]. Likewise, U.S. regulations allow credit scores to use `age` if it does  
90 not harm older applicants [15]. In such cases, models should use these attributes in a way that leads  
91 to tailored performance gains for every group.

92 *Sensitive Data*: Models that use attributes like `hiv` status should guarantee a tailored improvement  
93 performance for the sensitive group, `hiv = +`. Otherwise, it would be better not to solicit this  
94 information in the first place as the information could inflict harm when leaked [see e.g., 6].

95 *Self-Reported Data*: Certain kinds of models require users to report their data at prediction time [see  
96 e.g., self-report diagnostics 42, 67]. These models should obey fair use conditions to incentivize users  
97 to report their data truthfully (see Remark 2)

98 *Costly Data*: Group attributes can encode data collected at prediction time — e.g., an attribute like  
99 `tumor_subtype` whose value can only be determined by an invasive medical test. Models that  
100 ensure fair use with respect to `tumor_subtype` guarantee that patients with a specific type of tumor  
101 will not receive a less accurate prediction after undergoing the procedure.

## 102 3 Failure Modes of Personalization

103 In this section, we describe how common approaches to personalization can reduce performance for  
104 specific groups. Our goal is to highlight failure modes that apply to a broad range of prediction tasks.  
105 We pair each failure mode with toy examples, focusing on simple classification tasks that can be  
106 checked manually.<sup>2</sup>

### 107 3.1 Model Specification

108 We start with misspecification – i.e., when we fit models that cannot represent the role of group  
109 membership in the data distribution. A common form of misspecification occurs when we personalize

---


<sup>2</sup>In most cases, we train a linear classifier that minimizes the error rate on a *perfectly sampled* training dataset – i.e., where  $\frac{1}{n} \sum_{i=1}^n 1[\mathbf{x}_i = \mathbf{x}, y_i = y, \mathbf{g}_i = \mathbf{g}] = \mathbb{P}(\mathbf{x}, y, \mathbf{g})$  for all  $(\mathbf{x}, y, \mathbf{g}) \in \mathcal{X} \times \mathcal{Y} \times \mathcal{G}$ . This condition ensures that the training error matches the test error.

Group	Data		Predictions		Mistakes		Gain
	$n_g^+$	$n_g^-$	$h_0$	$h_g$	$R_g(h_0)$	$R_g(h_g)$	$\Delta R_g(h_g, h_0)$
young, female	0	24	-	+	0	24	-24
young, male	25	0	-	+	25	0	25
old, female	25	0	-	+	25	0	25
old, male	0	27	-	-	0	0	0
<b>Total</b>	50	51			50	24	26

**Figure 2:** Fair use violations due to model misspecification. Here, we are given  $n^+ = 50$  positive examples and  $n^- = 51$  negative examples for 2D classification task where  $g \in \{\text{male}, \text{female}\} \times \{\text{old}, \text{young}\}$ . We fit two linear classifiers:  $h_0$ , a generic model without group attributes, and  $h_g$  a personalized model with a one-hot encoding. As shown, personalization reduces overall error from 50 to 24. However, not all groups benefit from personalization: (young, female) now receives less accurate predictions while (old, male) receives no gain. Here,  $h_g$  also violates envy-freeness for (young, female) as individuals in this group would receive more accurate predictions by misreporting their group membership as (old, male).

110 simple models using a one-hot encoding. In such cases, models exhibit fair use violations on data  
 111 distributions that exhibit intersectionality (see Figure 2). Consider, for example, a logistic regression  
 112 model with a one-hot encoding that assigns higher risk to patients who are old and to patients who  
 113 are male. This would lead to a fair use violation for patients who are old *and* male if their true risk  
 114 were lower than either group alone.

115 Misspecification can also arise due to a failure to account for group-specific interaction effects – e.g.,  
 116 instances where group attributes act as mediator or moderator variables [see e.g., 7]. In Figure 3, we  
 117 show an example that exhibits the hallmarks of personalization: a generic model performs poorly on  
 118 on “heterogeneous” groups  $A$  and  $C$ , and a personalized model that accounts for group membership  
 119 improves overall performance by assigning more accurate predictions to  $A$  and  $C$ . In this case, the  
 120 resulting model exhibits a fair use violation for group  $B$  because a generic model performs as well as  
 121 possible for group  $B$ .



**Figure 3:** Fair use violation resulting from model misspecification. We consider a 2D classification task with heterogeneous groups  $g = \{A, B, C\}$  where an ideal model should assign a personalized intercept to each group *and* a personalized slope to group  $B$ . In this case, a personalized model with a one-hot encoding would fit a personalized intercept for each group, but fail to fit a personalized slope for group  $B$ . The personalized model would improve overall performance by assigning more accurate predictions to groups  $A$  and  $C$ . However, it would result in a fair use violation by performing *worse* for group  $B$ .

122 In practice, we can avoid these issues by either fitting models that are rich enough to capture these  
 123 effects, or by training a separate model for each group. Both are challenging in tasks with multiple  
 124 groups as we must either specify interactions for each group, or fit models using a limited amount of  
 125 data for each group.

### 126 3.2 Model Selection

127 Model development often involves choosing one model from a family of candidate models – e.g.,  
 128 when we set a regularization penalty to avoid overfitting, or choose a subset of variables to improve  
 129 usability. Common criteria for model selection consist choosing a model on the basis of population-  
 130 level performance [e.g., mean K-CV test error 4]. In practice, this choice can lead to models that  
 131 reduce performance for a specific group. We demonstrate this effect in Figure 4. The example

132 highlights how fair use violations may be unavoidable in settings where we are forced to assign  
133 predictions with a single model – as there may not exist a model that ensure fair use for all groups.

### 134 3.3 Other Failure Modes & Discussion

135 Work in personalization naturally presumes that fitting a model with group attributes will provide  
136 a uniform performance gain to all groups. In practice, however, this only holds under restrictive  
137 assumptions. We include a similar discussion of other failure modes along with examples in Appendix  
138 E including: training with a surrogate loss function; generalization; and dataset shifts. The failure  
139 models that we have covered in this section are chosen since they motivate potential interventions for  
140 model development. For example, one could avoid the fair use violations in Figure 2 by using an  
141 intersectional one-hot encoding, and avoid violations across across all cases by training decoupled  
142 models.

## 143 4 Empirical Study

144 In this section, we study fair use in clinical prediction models – i.e. models that routinely include  
145 group attributes where fair use violations inflict harm. Our goals are to measure the prevalence of fair  
146 use violations and to evaluate how these change as a result of interventions in model development. We  
147 attach all software to reproduce the results in this section to our submission, and include additional  
148 details on our setup and additional experimental results in the supplement.

### 149 4.1 Setup

150 We work with 6 datasets for clinical prediction tasks (see Table 1). We split each dataset into a  
151 training sample (80%) to fit models, and a test sample (20%) to evaluate the gains of personalization.  
152 We use the training data from each dataset to fit 9 kinds of personalized models. Each personalized  
153 model belongs to one of 3 model classes: *logistic regression* (LR), *random forests* (RF), and *neural*  
154 *nets* (NN); and accounts for group membership using one of 3 personalization techniques.

155 The three personalization techniques being: *One-hot Encoding* (1Hot): We fit a model with dummy  
156 variables for each group attribute, *Intersectional Encoding* (All): We fit a model with dummy variables  
157 for each intersectional group, and *Decoupling* (DCP): We fit a model for each intersectional group  
158 using its own data. The three techniques represent increasingly complex ways to account for group  
159 membership where complexity is measured by the interactions between group attributes and other  
160 features: 1Hot reflect no interactions; All reflect interactions between group attributes; and DCP  
161 reflects all possible attributes between group attributes and features.

162 We evaluate the gains of personalization for each model in terms of three performance metrics: (1)  
163 *error rate*, which reflects the accuracy of yes-or-no predictions [for a diagnostic test, e.g., 26]; (2)  
164 *expected calibration error* (ECE), which measures the reliability of risk predictions [for a medical  
165 risk score, e.g., 13]; (3) *area under ROC curve* (AUC), which measures accuracy in ranking [for a  
166 prioritization tool, e.g., 77].

### 167 4.2 Results

168 We summarize our results for logistic regression in Table 1 and for other model classes in Appendix G.  
169

170 **On Prevalence** Our results show that personalized models can improve performance at a population  
171 level yet reduce performance for specific groups. These fair use violations arise across datasets,  
172 personalization techniques, and model classes. Consider the standard configuration used to develop  
173 clinical prediction models – i.e., a logistic regression model with a one-hot encoding of group  
174 attributes (LR+1Hot). Here, we find that at least one group experiences a statistically significant fair  
175 use violation in terms of error on 4/6 datasets (5/6 for AUC and ECE).

176 **On Personalization Techniques** Our results show that there is no one personalization technique  
177 that minimizes fair use violations. In Table 1, for example, the best personalization technique for  
178 `cardio_eicu` is intersectional encoding while the best personalization technique for `mortality`

Dataset	Metrics	Test AUC			Test ECE			Test Error		
		1Hot	All	DCP	1Hot	All	DCP	1Hot	All	DCP
apnea $n = 1152, d = 26$ $\mathcal{G} = \{\text{age, sex}\}$ $m = 6$ [66]	Personalized	0.750	0.750	0.803	7.5%	5.5%	7.2%	34.2%	33.8%	26.2%
	Gain	0.001	0.000	0.053	-1.5%	0.6%	-1.1%	-1.0%	-0.7%	7.0%
	Best/Worst Gain	0.002 / -0.001	0.001 / -0.016	0.119 / -0.005	0.7% / -7.1%	0.7% / -4.6%	1.7% / -6.6%	0.0% / -9.9%	1.8% / -7.8%	21.7% / -7.8%
	Rat. Gains/VIols	1/2	1/4	4/0	1/3	1/3	2/2	0/4	1/3	4/1
EF Gains/VIols	0/0	0/0	3/0	0/3	0/3	4/0	0/6	0/5	4/1	
cardio_eicu $n = 1341, d = 49$ $\mathcal{G} = \{\text{age, sex}\}$ $m = 4$ [60]	Personalized	0.768	0.767	0.762	4.4%	4.6%	8.9%	29.1%	29.1%	29.5%
	Gain	0.000	-0.001	-0.007	0.4%	0.2%	-4.1%	-0.4%	-0.4%	-0.9%
	Best/Worst Gain	0.002 / -0.001	0.001 / -0.001	0.094 / -0.099	1.6% / -1.5%	0.9% / -0.2%	-1.1% / -6.3%	0.0% / -3.1%	0.2% / -3.1%	12.9% / -8.9%
	Rat. Gains/VIols	2/2	2/1	1/2	2/1	1/0	0/4	0/2	1/2	2/2
EF Gains/VIols	0/0	0/0	3/1	0/2	0/2	1/1	0/3	0/3	3/1	
cardio_mimic $n = 3289, d = 49$ $\mathcal{G} = \{\text{age, sex}\}$ $m = 4$ [38]	Personalized	0.854	0.854	0.870	2.1%	2.3%	2.3%	23.3%	23.4%	21.4%
	Gain	0.001	0.001	0.017	-0.4%	-0.5%	-0.6%	0.3%	0.3%	2.2%
	Best/Worst Gain	0.001 / -0.000	0.001 / -0.000	0.051 / 0.006	0.5% / 0.4%	0.6% / -0.2%	0.6% / -2.3%	0.9% / -0.1%	0.9% / -0.1%	7.6% / -0.2%
	Rat. Gains/VIols	2/1	2/1	4/0	4/0	3/0	1/2	3/0	3/0	3/0
EF Gains/VIols	0/0	0/0	4/0	1/3	0/1	3/1	0/3	0/3	4/0	
heart $n = 181, d = 26$ $\mathcal{G} = \{\text{sex, age}\}$ $m = 4$ [17]	Personalized	0.870	0.846	0.817	8.4%	17.8%	17.5%	19.7%	19.7%	15.8%
	Gain	-0.007	-0.030	-0.060	2.8%	-6.6%	-6.3%	-1.3%	-1.3%	2.6%
	Best/Worst Gain	0.007 / -0.031	0.024 / -0.050	0.039 / -0.190	4.4% / -0.6%	-1.8% / -3.1%	10.1% / -4.6%	0.0% / -6.1%	0.0% / -12.1%	10.6% / -8.4%
	Rat. Gains/VIols	1/1	1/1	0/3	2/1	0/4	2/1	0/1	0/3	2/1
EF Gains/VIols	0/0	0/0	1/2	0/2	0/3	2/2	0/1	0/1	2/1	
mortality $n = 25366, d = 468$ $\mathcal{G} = \{\text{age, sex}\}$ $m = 6$ [38]	Personalized	0.848	0.848	0.880	2.0%	2.1%	2.5%	23.6%	23.4%	20.2%
	Gain	0.000	0.001	0.033	0.2%	0.1%	-0.3%	-0.2%	-0.0%	3.2%
	Best/Worst Gain	0.005 / -0.001	0.005 / -0.000	0.111 / 0.012	1.5% / 0.1%	2.6% / -0.3%	11.2% / -2.4%	0.8% / -2.5%	2.1% / -0.4%	20.1% / -0.5%
	Rat. Gains/VIols	3/3	3/2	6/0	5/0	5/1	3/2	2/4	3/2	5/1
EF Gains/VIols	0/0	0/0	6/0	1/1	3/2	5/1	0/4	1/4	6/0	
saps $n = 7797, d = 36$ $\mathcal{G} = \{\text{hiv, age}\}$ $m = 4$ [3]	Personalized	0.890	0.890	0.888	1.5%	1.5%	2.0%	18.9%	18.9%	18.5%
	Gain	0.001	0.001	-0.001	0.1%	0.1%	-0.4%	0.0%	0.0%	0.4%
	Best/Worst Gain	0.014 / -0.000	0.014 / -0.001	0.017 / -0.246	2.8% / -1.5%	2.4% / -0.6%	9.4% / -19.1%	19.0% / -10.4%	0.8% / -10.4%	3.5% / -23.3%
	Rat. Gains/VIols	1/1	1/1	2/2	2/0	2/1	2/2	2/1	1/3	2/1
EF Gains/VIols	0/0	0/0	2/1	2/2	2/2	3/1	1/1	2/2	2/2	

**Table 1:** Performance of personalized logistic regression models on all datasets. We show the gains of personalization in terms of test AUC, ECE, and error. We report: model performance at the population level, the overall gain of personalization, the range of gains over  $m$  intersectional groups, and the number of rationality and envy-freeness gains/violations (evaluated using a bootstrap hypothesis test at a 10% significance level).

179 was decoupling. These strategies change across model classes – as the corresponding strategies  
180 for neural networks for `cardio_eicu` and `mortality` are decoupling and using an intersectional  
181 encoding, respectively (see Appendix G). In general, even strategies that exhibit few violations can  
182 fail critically. For example, LR+DCP for `saps` leads to a 10% increase in error for `HIV+ & >30`.  
183 Overall, these results suggest that the most consistent way to avoid the harm from a fair use violation  
184 is to check.

185 **On Interventions in Model Development** Our results show that routine decisions in model de-  
186 velopment can produce considerable differences in group-level performance and fair use violations.  
187 This suggests that if we are able to spot fair use violations, we may be able to minimize them by  
188 “interventions” to model development. In light of this, we consider interventions that address the  
189 failure modes in Section 3 – e.g., using an intersectional one-hot encoding, training decoupled models,  
190 and equalizing sample sizes.

191 In general, we find that applying these strategies can minimize fair use violations often. For example,  
192 we can eliminate all fair use violations for `cardio_mimic` in our standard configuration by training  
193 decoupled models. However, there is no “best” intervention that consistently resolve these violations.  
194 Typically, this is because an intervention that resolves a violation for one group will precipitate a  
195 violation for others. In `cardio_eicu`, for instances, a logistic regression model fit with a onehot  
196 encoding will exhibit a violation on old males. Switching an intersectional encoding will fix this  
197 violation but introduce a new one for old females.

198 **On the Reliability of Gains & Violations** Our results underscore the need for reliable procedures  
199 to discover fair use violations or claim gains from personalization. We can often find detectable  
200 instances of benefit or harm. For example, we find that on `saps` in our default configuration that we  
201 detect a gain from personalization for patients who are HIV negative and older than 30. Additionally,  
202 in `cardio_eicu` when training LR+All we detect a fair use violation for patients who are old females  
203 (see e.g., Rat Gains/Violations in Table 1). One actionable finding from an evaluation of the gains of  
204 personalization is a group does not experience a meaningful gain nor harm due to personalization. In  
205 such cases, one may wish to intervene to avoid soliciting unnecessary data: when group attributes  
206 encode information that is sensitive or that must be collected at prediction time (e.g., `hiv_status`  
207 or `tumor_subtype`), we may prefer to avoid soliciting information that is demonstrably useful for  
208 prediction.

209 **References**

- 210 [1] Agarwal, A., Beygelzimer, A., Dudík, M., Langford, J., and Wallach, H. A Reductions Approach to Fair  
211 Classification. In *Proceedings of the 35th International Conference on Machine Learning*, Proceedings of  
212 Machine Learning Research. PMLR, 2018.
- 213 [2] Agresti, A. *An introduction to categorical data analysis*. John Wiley & Sons, 2018.
- 214 [3] Allyn, J., Ferdynus, C., Bohrer, M., Dalban, C., Valance, D., and Allou, N. Simplified acute physiology  
215 score ii as predictor of mortality in intensive care units: a decision curve analysis. *PloS one*, 11(10):  
216 e0164828, 2016.
- 217 [4] Arlot, S. and Celisse, A. A survey of cross-validation procedures for model selection. *Statistics surveys*, 4:  
218 40–79, 2010.
- 219 [5] Balcan, M.-F., Dick, T., Noothigattu, R., and Procaccia, A. D. Envy-free classification. *arXiv preprint*  
220 *arXiv:1809.08700*, 2018.
- 221 [6] Bansal, G., Gefen, D., et al. The impact of personal dispositions on information sensitivity, privacy concern  
222 and trust in disclosing health information online. *Decision support systems*, 49(2):138–150, 2010.
- 223 [7] Baron, R. M. and Kenny, D. A. The moderator–mediator variable distinction in social psychological  
224 research: Conceptual, strategic, and statistical considerations. *Journal of personality and social psychology*,  
225 51(6):1173, 1986.
- 226 [8] Beauchamp, T. L., Childress, J. F., et al. *Principles of Biomedical Ethics*. Oxford University Press, USA,  
227 2001.
- 228 [9] Bertsimas, D. and Kallus, N. From predictive to prescriptive analytics. *Management Science*, 66(3):  
229 1025–1044, 2020.
- 230 [10] Bertsimas, D., Dunn, J., and Mundru, N. Optimal prescriptive trees. *INFORMS Journal on Optimization*, 1  
231 (2):164–183, 2019.
- 232 [11] Bien, J., Taylor, J., and Tibshirani, R. A lasso for hierarchical interactions. *Annals of statistics*, 41(3):1111,  
233 2013.
- 234 [12] Biggs, M., Sun, W., and Ettl, M. Model distillation for revenue optimization: Interpretable personalized  
235 pricing. *arXiv preprint arXiv:2007.01903*, 2020.
- 236 [13] Blaha, M. J. The critical importance of risk score calibration: time for transformative approach to risk  
237 score validation?, 2016.
- 238 [14] Celis, L. E., Huang, L., Keswani, V., and Vishnoi, N. K. Classification with fairness constraints: A  
239 meta-algorithm with provable guarantees. In *Proceedings of the Conference on Fairness, Accountability,*  
240 *and Transparency*, pp. 319–328. ACM, 2019.
- 241 [15] Commission, F. T. Equal credit opportunity act. [https://www.fdic.gov/resources/supervision-and-](https://www.fdic.gov/resources/supervision-and-examinations/consumer-compliance-examination-manual/documents/5/v-7-1.pdf)  
242 [examinations/consumer-compliance-examination-manual/documents/5/v-7-1.pdf](https://www.fdic.gov/resources/supervision-and-examinations/consumer-compliance-examination-manual/documents/5/v-7-1.pdf), 2020.
- 243 [16] Corbett-Davies, S. and Goel, S. The measure and mismeasure of fairness: A critical review of fair machine  
244 learning. *arXiv preprint arXiv:1808.00023*, 2018.
- 245 [17] Detrano, R., Janosi, A., Steinbrunn, W., Pfisterer, M., Schmid, J.-J., Sandhu, S., Guppy, K. H., Lee, S., and  
246 Froelicher, V. International application of a new probability algorithm for the diagnosis of coronary artery  
247 disease. *The American journal of cardiology*, 64(5):304–310, 1989.
- 248 [18] DiCiccio, T. J. and Efron, B. Bootstrap confidence intervals. *Statistical science*, pp. 189–212, 1996.
- 249 [19] Dietterich, T. G. Approximate statistical tests for comparing supervised classification learning algorithms.  
250 *Neural computation*, 10(7):1895–1923, 1998.
- 251 [20] Do, V., Corbett-Davies, S., Atif, J., and Usunier, N. Online certification of preference-based fairness for  
252 personalized recommender systems. *arXiv preprint arXiv:2104.14527*, 2021.
- 253 [21] Dunn, O. J. Multiple comparisons among means. *Journal of the American statistical association*, 56(293):  
254 52–64, 1961.
- 255 [22] Dwork, C., Hardt, M., Pitassi, T., Reingold, O., and Zemel, R. Fairness through awareness. In *Proceedings*  
256 *of the 3rd innovations in theoretical computer science conference*, pp. 214–226, 2012.

- 257 [23] Dwork, C., Immorlica, N., Kalai, A. T., and Leiserson, M. Decoupled classifiers for group-fair and efficient  
258 machine learning. In *Proceedings of the 1st Conference on Fairness, Accountability and Transparency*,  
259 volume 81 of *Proceedings of Machine Learning Research*, pp. 119–133. PMLR, 2018.
- 260 [24] Elmachtoub, A. N., Gupta, V., and Hamilton, M. The value of personalized pricing. *Available at SSRN*  
261 *3127719*, 2018.
- 262 [25] Eneanya, N. D., Yang, W., and Reese, P. P. Reconsidering the consequences of using race to estimate  
263 kidney function. *Jama*, 322(2):113–114, 2019.
- 264 [26] Eusebi, P. Diagnostic accuracy measures. *Cerebrovascular Diseases*, 36(4):267–272, 2013.
- 265 [27] Fan, H. and Poole, M. S. What is personalization? perspectives on the design and implementation of  
266 personalization in information systems. *Journal of Organizational Computing and Electronic Commerce*,  
267 16(3-4):179–202, 2006.
- 268 [28] Feldman, M., Friedler, S. A., Moeller, J., Scheidegger, C., and Venkatasubramanian, S. Certifying and  
269 removing disparate impact. In *Proceedings of the 21th ACM SIGKDD International Conference on*  
270 *Knowledge Discovery and Data Mining*, pp. 259–268. ACM, 2015.
- 271 [29] Finlayson, S. G., Subbaswamy, A., Singh, K., Bowers, J., Kupke, A., Zittrain, J., Kohane, I. S., and Saria,  
272 S. The clinician and dataset shift in artificial intelligence. *The New England journal of medicine*, 385(3):  
273 283–286, 2021.
- 274 [30] Gneiting, T. and Raftery, A. E. Strictly proper scoring rules, prediction, and estimation. *Journal of the*  
275 *American statistical Association*, 102(477):359–378, 2007.
- 276 [31] Gulshan, V., Peng, L., Coram, M., Stumpe, M. C., Wu, D., Narayanaswamy, A., Venugopalan, S., Widner,  
277 K., Madams, T., Cuadros, J., et al. Development and validation of a deep learning algorithm for detection  
278 of diabetic retinopathy in retinal fundus photographs. *Jama*, 316(22):2402–2410, 2016.
- 279 [32] Guo, L. L., Pfohl, S. R., Fries, J., Posada, J., Fleming, S. L., Aftandilian, C., Shah, N., and Sung, L.  
280 Systematic review of approaches to preserve machine learning performance in the presence of temporal  
281 dataset shift in clinical medicine. *Applied Clinical Informatics*, 12(04):808–815, 2021.
- 282 [33] Hardt, M., Price, E., Srebro, N., et al. Equality of opportunity in supervised learning. In *Advances in*  
283 *Neural Information Processing Systems*, pp. 3315–3323, 2016.
- 284 [34] Harutyunyan, H., Khachatrian, H., Kale, D. C., Ver Steeg, G., and Galstyan, A. Multitask learning and  
285 benchmarking with clinical time series data. *Scientific data*, 6(1):1–18, 2019.
- 286 [35] Hébert-Johnson, Ú., Kim, M., Reingold, O., and Rothblum, G. Multicalibration: Calibration for the  
287 (computationally-identifiable) masses. In *Proceedings of the International Conference on Machine*  
288 *Learning*, pp. 1944–1953, 2018.
- 289 [36] Hu, L. and Chen, Y. Fair Classification and Social Welfare. *arXiv preprint arXiv:1905.00147*, 2019.
- 290 [37] Jaques, N., Taylor, T. S., Nosakhare, N. E., Sano, S. A., and Picard R. . P. R. Multi-task learning for  
291 predicting health, stress, and happiness. *Neural Information Processing Systems (NeurIPS) Workshop on*  
292 *Machine Learning for Healthcare*, 2016.
- 293 [38] Johnson, A. E., Pollard, T. J., Shen, L., Li-Wei, H. L., Feng, M., Ghassemi, M., Moody, B., Szolovits, P.,  
294 Celi, L. A., and Mark, R. G. Mimic-iii, a freely accessible critical care database. *Scientific data*, 3(1):1–9,  
295 2016.
- 296 [39] Jovanovic, B. Truthful disclosure of information. *The Bell Journal of Economics*, pp. 36–44, 1982.
- 297 [40] Kearns, M., Neel, S., Roth, A., and Wu, Z. S. Preventing fairness gerrymandering: Auditing and learning for  
298 subgroup fairness. In *Proceedings of the 35th International Conference on Machine Learning*, Proceedings  
299 of Machine Learning Research. PMLR, 2018.
- 300 [41] Kent, D. M., Paulus, J. K., Van Klaveren, D., D’Agostino, R., Goodman, S., Hayward, R., Ioannidis, J. P.,  
301 Patrick-Lake, B., Morton, S., Pencina, M., et al. The predictive approaches to treatment effect heterogeneity  
302 (path) statement. *Annals of internal medicine*, 172(1):35–45, 2020.
- 303 [42] Kessler, R. C., Adler, L., Ames, M., Demler, O., Faraone, S., Hiripi, E., Howes, M. J., Jin, R., Secnik, K.,  
304 Spencer, T., et al. The world health organization adult adhd self-report scale (asrs): a short screening scale  
305 for use in the general population. *Psychological medicine*, 35(2):245–256, 2005.



- 306 [43] Kim, M. P., Korolova, A., Rothblum, G. N., and Yona, G. Preference-informed fairness. *arXiv preprint*  
307 *arXiv:1904.01793*, 2019.
- 308 [44] Kiviat, B. The moral limits of predictive practices: The case of credit-based insurance scores. *American*  
309 *Sociological Review*, 84(6):1134–1158, 2019.
- 310 [45] Kiviat, B. Which data fairly differentiate? american views on the use of personal data in two market  
311 settings. *Sociological Science*, 8:26–47, 2021.
- 312 [46] Kleinberg, J., Ludwig, J., Mullainathan, S., and Rambachan, A. Algorithmic Fairness. In *AEA Papers and*  
313 *Proceedings*, volume 108, pp. 22–27, 2018.
- 314 [47] Kravitz, R. L., Duan, N., and Braslow, J. Evidence-based medicine, heterogeneity of treatment effects, and  
315 the trouble with averages. *The Milbank Quarterly*, 82(4):661–687, 2004.
- 316 [48] Le Gall, J.-R., Lemeshow, S., and Saulnier, F. A new simplified acute physiology score (saps ii) based on a  
317 european/north american multicenter study. *Jama*, 270(24):2957–2963, 1993.
- 318 [49] Lim, M. and Hastie, T. Learning interactions via hierarchical group-lasso regularization. *Journal of*  
319 *Computational and Graphical Statistics*, 24(3):627–654, 2015.
- 320 [50] Lipton, Z., McAuley, J., and Chouldechova, A. Does mitigating ml’s impact disparity require treatment  
321 disparity? In *Advances in Neural Information Processing Systems 31*, pp. 8135–8145, 2018.
- 322 [51] Martinez, N., Bertran, M., and Sapiro, G. Fairness with minimal harm: A pareto-optimal approach for  
323 healthcare. *arXiv preprint arXiv:1911.06935*, 2019.
- 324 [52] Martinez, N., Bertran, M., and Sapiro, G. Minimax pareto fairness: A multi objective perspective. In  
325 *International Conference on Machine Learning*, pp. 6755–6764. PMLR, 2020.
- 326 [53] Metaxa, D., Park, J. S., Robertson, R. E., Karahalios, K., Wilson, C., Hancock, J., Sandvig, C., et al.  
327 Auditing algorithms: Understanding algorithmic systems from the outside in. *Foundations and Trends®*  
328 *in Human–Computer Interaction*, 14(4):272–344, 2021.
- 329 [54] Naeini, M. P., Cooper, G., and Hauskrecht, M. Obtaining well calibrated probabilities using bayesian  
330 binning. In *Twenty-Ninth AAAI Conference on Artificial Intelligence*, 2015.
- 331 [55] Narasimhan, H. Learning with complex loss functions and constraints. In *International Conference on*  
332 *Artificial Intelligence and Statistics*, pp. 1646–1654, 2018.
- 333 [56] Paulus, J. K., Wessler, B. S., Lundquist, C., Lai, L. L., Raman, G., Lutz, J. S., and Kent, D. M. Field  
334 synopsis of sex in clinical prediction models for cardiovascular disease. *Circulation: Cardiovascular*  
335 *Quality and Outcomes*, 9(2\_suppl\_1):S8–S15, 2016.
- 336 [57] Perez-Rodriguez, J. and de la Fuente, A. Now is the time for a postracial medicine: Biomedical research,  
337 the national institutes of health, and the perpetuation of scientific racism. *The American Journal of*  
338 *Bioethics*, 17(9):36–47, 2017.
- 339 [58] Pfohl, S., Marafino, B., Coulet, A., Rodriguez, F., Palaniappan, L., and Shah, N. H. Creating fair models  
340 of atherosclerotic cardiovascular disease risk. In *Proceedings of the 2019 AAAI/ACM Conference on AI,*  
341 *Ethics, and Society*, pp. 271–278, 2019.
- 342 [59] Platt, J. et al. Probabilistic outputs for support vector machines and comparisons to regularized likelihood  
343 methods. *Advances in large margin classifiers*, 10(3):61–74, 1999.
- 344 [60] Pollard, T. J., Johnson, A. E., Raffa, J. D., Celi, L. A., Mark, R. G., and Badawi, O. The eicu collaborative  
345 research database, a freely available multi-center database for critical care research. *Scientific data*, 5(1):  
346 1–13, 2018.
- 347 [61] Quiñonero-Candela, J., Sugiyama, M., Schwaighofer, A., and Lawrence, N. D. *Dataset shift in machine*  
348 *learning*. Mit Press, 2008.
- 349 [62] Savage, L. J. Elicitation of personal probabilities and expectations. *Journal of the American Statistical*  
350 *Association*, 66(336):783–801, 1971.
- 351 [63] Steyerberg, E. W. et al. *Clinical prediction models*. Springer, 2019.
- 352 [64] Suresh, H., Hunt, N., Johnson, A., Celi, L. A., Szolovits, P., and Ghassemi, M. Clinical intervention  
353 prediction and understanding with deep neural networks. In *Machine Learning for Healthcare Conference*,  
354 pp. 322–337. PMLR, 2017.

- 355 [65] Taylor, S., Jaques, N., Nosakhare, E., Sano, A., and Picard, R. Personalized multitask learning for predicting  
356 tomorrow’s mood, stress, and health. *IEEE Transactions on Affective Computing*, 11(2):200–213, 2017.
- 357 [66] Ustun, B., Westover, M. B., Rudin, C., and Bianchi, M. T. Clinical prediction models for sleep apnea: the  
358 importance of medical history over symptoms. *Journal of Clinical Sleep Medicine*, 12(02):161–168, 2016.
- 359 [67] Ustun, B., Adler, L. A., Rudin, C., Faraone, S. V., Spencer, T. J., Berglund, P., Gruber, M. J., and Kessler,  
360 R. C. The world health organization adult attention-deficit/hyperactivity disorder self-report screening  
361 scale for dsm-5. *Jama psychiatry*, 74(5):520–527, 2017.
- 362 [68] Ustun, B., Liu, Y., and Parkes, D. Fairness without harm: Decoupled classifiers with preference guarantees.  
363 In *International Conference on Machine Learning*, pp. 6373–6382, 2019.
- 364 [69] Vaughan, G., Aseltine, R., Chen, K., and Yan, J. Efficient interaction selection for clustered data via  
365 stagewise generalized estimating equations. *Statistics in Medicine*, 39(22):2855–2868, 2020.
- 366 [70] Viviano, D. and Bradic, J. Fair policy targeting. *arXiv preprint arXiv:2005.12395*, 2020.
- 367 [71] Vyas, D. A., Eisenstein, L. G., and Jones, D. S. Hidden in plain sight—reconsidering the use of race  
368 correction in clinical algorithms, 2020.
- 369 [72] Wang, H., Ustun, B., and Calmon, F. P. Repairing without retraining: Avoiding disparate impact with  
370 counterfactual distributions. In *Proceedings of the 36th International Conference on Machine Learning*,  
371 *Proceedings of Machine Learning Research*. PMLR, 2019.
- 372 [73] Yala, A., Lehman, C., Schuster, T., Portnoi, T., and Barzilay, R. A deep learning mammography-based  
373 model for improved breast cancer risk prediction. *Radiology*, 292(1):60–66, 2019.
- 374 [74] Zafar, M. B., Valera, I., Gomez Rodriguez, M., and Gummadi, K. P. Fairness beyond disparate treatment  
375 and disparate impact: Learning classification without disparate mistreatment. In *Proceedings of the 26th*  
376 *International Conference on World Wide Web*, pp. 1171–1180. International World Wide Web Conferences  
377 Steering Committee, 2017.
- 378 [75] Zafar, M. B., Valera, I., Rodriguez, M., Gummadi, K., and Weller, A. From parity to preference-based  
379 notions of fairness in classification. In *Advances in Neural Information Processing Systems*, pp. 228–238,  
380 2017.
- 381 [76] Zafar, M. B., Valera, I., Rogriguez, M. G., and Gummadi, K. P. Fairness Constraints: Mechanisms for Fair  
382 Classification. In *Proceedings of the 20th International Conference on Artificial Intelligence and Statistics*,  
383 volume 54 of *Proceedings of Machine Learning Research*, pp. 962–970. PMLR, 20–22 Apr 2017.
- 384 [77] Zhan, Q., Sierra, E., Malmsten, J., Ye, Z., Rosenwaks, Z., and Zaninovic, N. Blastocyst score, a blastocyst  
385 quality ranking tool, is a predictor of blastocyst ploidy and implantation potential. *F&S Reports*, 1(2):  
386 133–141, 2020.
- 387 [78] Zhu, X., Yao, J., and Huang, J. Deep convolutional neural network for survival analysis with pathological  
388 images. In *2016 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)*, pp. 544–547.  
389 IEEE, 2016.

390 **Checklist**

- 391 1. For all authors...
- 392 1. Do the main claims made in the abstract and introduction accurately reflect the paper’s contri-  
393 butions and scope? [Yes] ,
- 394 2. Did you describe the limitations of your work? [Yes] , see Section ??
- 395 3. Did you discuss any potential negative societal impacts of your work? [Yes] , see Section ??.
- 396 4. Have you read the ethics review guidelines and ensured that your paper conforms to them?  
397 [Yes] .
- 398 2. If you are including theoretical results...
- 399 1. Did you state the full set of assumptions of all theoretical results? [N/A]
- 400 2. Did you include complete proofs of all theoretical results? [N/A]
- 401 3. If you ran experiments...
- 402 1. Did you include the code, data, and instructions needed to reproduce the main experimental  
403 results (either in the supplemental material or as a URL)? [Yes]
- 404 2. Did you specify all the training details (e.g., data splits, hyperparameters, how they were  
405 chosen)? [Yes] , see Appendix G
- 406 3. Did you report error bars (e.g., with respect to the random seed after running experiments  
407 multiple times)? [Yes]
- 408 4. Did you include the total amount of compute and the type of resources used (e.g., type of  
409 GPUs, internal cluster, or cloud provider)? [Yes] , see Appendix G
- 410 4. If you are using existing assets (e.g., code, data, models) or curating/releasing new assets...
- 411 1. If your work uses existing assets, did you cite the creators? [Yes]
- 412 2. Did you mention the license of the assets? [N/A]
- 413 3. Did you include any new assets either in the supplemental material or as a URL? [No] ,
- 414 4. Did you discuss whether and how consent was obtained from people whose data you’re  
415 using/curating? [N/A]
- 416 5. Did you discuss whether the data you are using/curating contains personally identifiable  
417 information or offensive content? [Yes]
- 418 5. If you used crowdsourcing or conducted research with human subjects...
- 419 1. Did you include the full text of instructions given to participants and screenshots, if applicable?  
420 [N/A]
- 421 2. Did you describe any potential participant risks, with links to Institutional Review Board (IRB)  
422 approvals, if applicable? [N/A]
- 423 3. Did you include the estimated hourly wage paid to participants and the total amount spent on  
424 participant compensation? [N/A]

425 **A Notation**

426 Below we provide a table that consolidates and describes the notation used throughout the paper.

Symbol	Meaning
$\mathbf{x}_i = (x_{i,1}, x_{i,2}, \dots, x_{i,d})$	feature vector of example $i$
$y_i \in \mathcal{Y}$	label of example $i$
$\mathbf{g}_i \in \{g_{i,1}, g_{i,2}, \dots, g_{i,k}\}$	group membership of example $i$
$\mathcal{G} = \mathcal{G}_1 \times \mathcal{G}_2 \times \dots \times \mathcal{G}_k$	space of group attributes
$m =  \mathcal{G} $	number of intersectional groups
$n_g := \sum 1[\mathbf{g}_i = \mathbf{g}]$	number of examples of group $\mathbf{g} \in \mathcal{G}$
$n_g^+ := \sum 1[\mathbf{g}_i = \mathbf{g}, y_i = +1]$	number of examples of group $\mathbf{g} \in \mathcal{G}$ with $y_i = +1$
$n_g^- := \sum 1[\mathbf{g}_i = \mathbf{g}, y_i = -1]$	number of examples of group $\mathbf{g} \in \mathcal{G}$ with $y_i = -1$
$\mathcal{H}_0$	hypothesis class of generic model
$\mathcal{H}$	hypothesis class of personalized models
$h_0 \in \mathcal{X} \rightarrow \mathcal{Y}$	generic model
$h : \mathcal{X} \times \mathcal{G} \rightarrow \mathcal{Y}$	personalized model
$h_g : \mathcal{X} \times \mathcal{G} \rightarrow \mathcal{Y}$	personalized classifier where group membership is reported truthfully (as $\mathbf{g}$ )
$R_g(h_{g'})$	true risk of model $h$ of group $\mathbf{g}$ if they report $\mathbf{g}'$
$\hat{R}_g(h_{g'})$	empirical risk of model $h$ of group $\mathbf{g}$ if they report $\mathbf{g}'$
$\Delta_g(h, h')$	gain (i.e., reduction in true risk) for group $\mathbf{g}$ when using $h$ rather than $h'$
$\Delta_g(h_g, h_0)$	rationality gap for group $\mathbf{g}$ (performance gain when reporting $\mathbf{g}$ as opposed to concealing it)
$\Delta_g(h_g, h_{g'})$	rationality gap for group $\mathbf{g}$ (performance gain when reporting $\mathbf{g}$ as opposed to concealing it)

**Table 2:** Notation

427 **Preliminaries**

428 We start with a dataset of  $n$  examples  $(\mathbf{x}_i, y_i, \mathbf{g}_i)_{i=1}^n$ , where each example consists of a feature  
 429 vector  $\mathbf{x}_i = [x_{i,1}, \dots, x_{i,d}] \in \mathbb{R}^d$ , a label  $y_i \in \mathcal{Y}$ , and a vector of  $k$  categorical *group attributes*  
 430  $\mathbf{g}_i = [g_{i,1}, \dots, g_{i,k}] \in \mathcal{G}_1 \times \dots \times \mathcal{G}_k = \mathcal{G}$  – e.g.,  $\mathbf{g}_i = [\text{female}, \text{age} \geq 60, \text{blood\_type} = \text{O+}]$ .  
 431 We refer to  $\mathbf{g}_i$  as the *group membership* of  $i$  and to the set  $\{i \mid \mathbf{g}_i = \mathbf{g}\}$  as *group  $\mathbf{g}$* . We let  
 432  $n_g := |\{i \mid \mathbf{g}_i = \mathbf{g}\}|$  denote the number of examples in group  $\mathbf{g}$ , and let  $m := |\mathcal{G}|$  denote the number  
 433 of intersectional groups.

434 We use the data to fit a *personalized* model that uses group attributes  $h : \mathcal{X} \times \mathcal{G} \rightarrow \mathcal{Y}$ ; and a  
 435 *generic* model that does not  $h_0 : \mathcal{X} \rightarrow \mathcal{Y}$ . We fit both models via empirical risk minimization with  
 436 a loss function  $\ell : \mathcal{Y} \times \mathcal{Y} \rightarrow \mathbb{R}_+$ , using  $\hat{R}(h)$  and  $R(h)$  to denote the empirical risk and true risk,  
 437 respectively. We assume that the personalized and generic models represent the best models trained  
 438 on datasets with group attributes  $(\mathbf{x}_i, y_i, \mathbf{g}_i)_{i=1}^n$  and without them  $(\mathbf{x}_i, y_i)_{i=1}^n$ :

$$h \in \operatorname{argmin}_{h \in \mathcal{H}} \hat{R}(h) \quad h_0 \in \operatorname{argmin}_{h \in \mathcal{H}_0} \hat{R}(h)$$

439 We evaluate the gains of personalization for a personalized model  $h$  for each group. As part of  
 440 this evaluation, we examine how the performance of  $h$  for group  $\mathbf{g}$  changes when they are assigned  
 441 predictions that are personalized for another group  $\mathbf{g}'$  – i.e., the predictions that group  $\mathbf{g}$  would receive  
 442 by “misreporting” their group membership as  $\mathbf{g}'$ . We represent this formally by using  $h_{g'} := h(\cdot, \mathbf{g}')$   
 443 to denote a personalized model where group attributes are fixed to  $\mathbf{g}'$ . Given a personalized model  $h$ ,  
 444 we measure its *empirical risk* and *true risk* for group  $\mathbf{g}$  when they report group membership as  $\mathbf{g}'$  as:

$$\hat{R}_g(h_{g'}) := \frac{1}{n_g} \sum_{i: \mathbf{g}_i = \mathbf{g}} \ell(h(\mathbf{x}_i, \mathbf{g}'), y_i) \quad R_g(h_{g'}) := \mathbb{E}[\ell(h(\mathbf{x}, \mathbf{g}'), y) \mid \mathcal{G} = \mathbf{g}].$$

445 We assume that groups prefer models that assign more accurate predictions as measured in terms  
 446 of true risk. We express the preferences of group  $\mathbf{g}$  between  $h$  and  $h'$  using the *gain* measure  
 447  $\Delta_g(h, h') := R_g(h) - R_g(h')$ .

448 **B Related Work**

449 Our work is related to several streams of research in algorithmic fairness. We propose to check the  
 450 quality of personalization using preference-based notions of fairness [75, 68, 43, 70, 20]. We focus

451 on intersectional groups [c.f., 40, 35], which are more granular than those considered in the literature  
452 yet large enough to estimate performance [c.f., 22, 5]. We study models that use group attributes to  
453 assign more accurate predictions over a heterogeneous population. Several works highlight the need  
454 to account for group membership [75, 23, 16, 46, 50, 72], observing that it is otherwise impossible  
455 for a model to achieve *parity* – i.e., to perform equally well for all groups [33, 74, 76, 28, 1, 55, 14].  
456 Parity-based methods are ill-suited for personalization since they equalize performance by reducing  
457 performance for groups for who the model performs well, rather than improving performance for  
458 groups for who the model performs poorly [50, 36, 58, 51, 52].

459 We study personalization in models that encode personal characteristics through categorical attributes,  
460 which are widely used across medicine, consumer finance, and criminal justice (see use cases in §2).  
461 In medicine, for example, many models are fit using logistic regression with a one-hot encoding of  
462 categorical attributes [63, 71, 25]. Existing work that evaluates the gain of personalization often does  
463 so at population-level rather at the level of group who provide personal data [37, 65]. This population-  
464 level focus characterizes technical work in this area: recent methods use categorical attributes to  
465 improve population-level performance by accounting for heterogeneity – e.g., by automatically  
466 including higher-order interaction effects [11, 49, 69] or recursively partitioning data [24, 12, 10, 9].

467 **C Truthful Self-Reporting**

468 **Remark 2** (Truthful Self-Reporting). *Consider a prediction task where each person reports their*  
 469 *group membership to a personalized model. Let  $\mathbf{r}_i$  denote the self-reported group membership of*  
 470 *person  $i$  where:*

$$\mathbf{r}_i = \mathbf{g}_i \Leftrightarrow i \text{ reports truthfully} \quad \mathbf{r}_i \in \mathcal{G} \setminus \{\mathbf{g}_i\} \Leftrightarrow i \text{ misreports} \quad \mathbf{r}_i = ? \Leftrightarrow i \text{ withhold}$$

*If a personalized model  $h : \mathcal{X} \times \mathcal{G} \rightarrow \mathcal{Y}$  guarantees the fair use of a group attribute  $\mathcal{G}$  then each person would opt to truthfully report as this strategy would maximize their expected performance:*

$$\mathbf{g}_i \in \operatorname{argmin}_{\mathbf{r}_i \in \mathcal{G} \cup \{?\}} \mathbb{E}[\ell(h(\mathbf{x}, \mathbf{r}_i), y_i) \mid \mathcal{G} = \mathbf{g}_i].$$

471 Truthful reporting incentives reflect basic principles regarding *consent* in data privacy rights. In  
 472 effect, a personalized model that exhibits a fair use violation for a specific group uses their group  
 473 membership in a way that is coercive. If a group were allowed to report their personal information to  
 474 the model at prediction time, they would opt to withhold or misreport this information. With respect  
 475 to Definition 1, rationality ensures that a majority of  $\mathbf{g}$  prefer to report group membership rather than  
 476 withhold it. Envy-freeness ensures that a majority of group  $\mathbf{g}$  prefer to report group membership  
 477 rather than misreport it.

478 **D Testing & Verification**

479 Point estimates of the gains of personalization are not reliable, especially for small groups. In a  
 480 prediction task where a personalized model performs 5% worse than a generic model, a 5% drop  
 481 could represent 5 mistakes for a group with 100 samples, or 200 mistakes for a group with 4000  
 482 samples. Measuring the statistical significance of gains can help us distinguish between such cases  
 483 and inform our use of group attributes. In some applications, a significant fair use violation could  
 484 warrant the need for a new model. In others, we may wish to ensure a significant gain to use a group  
 485 attribute in the first place.

486 In practice, we check for a rationality violation using a one-sided hypothesis test of the form:

$$H_0 : R(h_0) - R(h_{\mathbf{g}}) \leq 0 \quad H_A : R(h_0) - R(h_{\mathbf{g}}) > 0$$

487 Here, the null hypothesis  $H_0$  assumes that group  $\mathbf{g}$  prefers  $h_{\mathbf{g}}$  to  $h_0$  by default. Thus, we reject  $H_0$   
 488 when there is enough evidence to support a rationality violation for  $\mathbf{g}$  in a held-out dataset.

489 We can use an inverted setup where  $H_A : R(h_0) - R(h_{\mathbf{g}}) < 0$  to check for gains from personal-  
 490 ization. The testing procedure varies based on the performance metric used to evaluate the gains of  
 491 personalization. In general, we can apply a bootstrap hypothesis test [18]. In some cases, there  
 492 exist more powerful tests for specific performance metrics [see e.g., the McNemar test for accuracy  
 493 19]. We can repeat these tests across multiple groups to check for envy-freeness, or to check for all  
 494 conditions in Definition 1. In the latter regimes, we can control for the false discovery rate using a  
 495 standard Bonferroni correction[21], which is suitable even for non-independent tests.

496 **E Failure Modes of Personalization**

497 In this Appendix, we describe additional mechanisms that lead personalized models to exhibit fair  
 498 use violations. The mechanisms below reflect failure modes that arise in later stages of the machine  
 499 learning pipeline, and that are more difficult to address through interventions.


500 **E.1 Model Selection**

501 **E.2 ERM with a Surrogate Loss Function**

502 Consider a setting where we want a personalized model that maximizes classification accuracy – i.e.,  
 503 one that minimizes the 0–1 loss. If we fit this classifier using a linear SVM – e.g., by solving an ERM  
 504 problem that optimizes the hinge loss – the approximation error between the 0-1 loss and the hinge  
 505 loss can produce a fair use violation (see Figure 5). This example is specifically designed to avoid  
 506 fair use violations that stem from model misspecification.

Data			Generic $h_0 = h_0(x_1) = h_0(x_2)$		Personalized Model (Selected) $h_S(x_1, g)$			Personalized Model (Discarded) $h_D(x_2, g)$		
			Pred.	Mistakes	Pred.	Error	Gain	Pred.	Error	Gain
$(g, x_1, x_2)$	$n^+$	$n^-$	$h_0$	$R(h_0)$	$h_S$	$R(h_S)$	$\Delta R_g(h_0, h_S)$	$h_D$	$R(h_D)$	$\Delta R_g(h_0, h_D)$
(0, 0, 0)	0	30	-	0	-	0	0	+	30	-30
(0, 0, 1)	0	0	-	0	-	0	0	-	0	0
(0, 1, 0)	0	20	-	0	+	20	-20	+	20	-20
(0, 1, 1)	0	0	-	0	+	0	0	-	0	0
(1, 0, 0)	25	0	-	25	+	0	25	+	0	25
(1, 0, 1)	0	0	-	0	+	0	0	-	0	0
(1, 1, 0)	15	0	-	15	+	0	15	+	0	15
(1, 1, 1)	0	0	-	0	-	0	0	-	0	0
Total	40	50		40		35	5		50	-10
$g = 0$	0	50		0		20	-20		50	-50
$g = 1$	40	0		40		15	25		0	40

**Figure 4:** Standard model selection criteria can lead to fair use violations. We consider a 2D classification task with two groups  $g \in \{0, 1\}$  where we need a model that can use at most one of the binary attributes  $(x_1, x_2) \in \{0, 1\}^2$ . We fit a generic model and a personalized model with a one-hot encoding of group membership choosing the variable that minimizes the overall error rate. Here, each group performs better under different choices, defaulting to choice that benefits the majority group.



**Figure 5:** Fair use violations resulting from the use of surrogate loss function in ERM. Here, we are given data for classification task with features  $\mathbf{x} = (x_1, x_2)$  and a group attribute  $g = \{A, B\}$ . We fit a linear SVM  $h_g$  by optimizing the hinge loss for a prediction task where evaluate the gains of personalization in terms of the error rate (i.e., 0-1 loss). In this case, the personalized model produces a fair use violation for Group B due to an outlier  $x_O$ . We plot the data for group A and group B separately. Each plot shows the generic classifier ( $h_0$ ; grey) and the personalized classifiers for the corresponding group ( $h_A$  or  $h_B$ ; black). As a baseline for comparison, we show the personalized models that we would obtain by optimizing an exact loss function (i.e., 0-1 loss, which matches the performance metric that we use to evaluate the gains for personalization). As shown, we would expect to avoid this violation had we fit a model by optimizing the 0-1 loss directly.

507 **E.3 Generalization & Dataset Shifts**

508 Fair use violations can arise in deployment. Small samples may significantly distort the relative  
 509 prevalence of each group, leading standard empirical risk minimization to fit a suboptimal generic  
 510 model or personalized model (see Figure 6). Fair use violations can also arise as a result of changes  
 511 in the data distribution [i.e., dataset shift 61, 29, 32] (see Figure 7)

Group		Training Data		Data Distribution		Model Predictions		Observed Performance			True Performance		
$g_1$	$g_2$	$n^+$	$n^-$	$n^+$	$n^-$	$h_0(\mathbf{x})$	$h_g(\mathbf{x}, g)$	$R_g(h_0)$	$R_g(h_g)$	$\Delta_g(h_g, h_0)$	$R_g(h_0)$	$R_g(h_g)$	$\Delta_g(h_g, h_0)$
0	0	65	60	130	120	+	+	60	60	0	120	120	0
1	0	60	65	120	130	+	-	65	60	5	130	120	10
0	1	60	65	130	120	+	-	65	60	5	120	130	-10
1	1	70	55	140	110	+	+	55	55	0	110	110	0
Total		255	245	520	480	-	N/A	245	235	10	480	470	0

**Figure 6:** Fair use violations can arise when personalizing models on small samples. Here, we show a 2D classification task in which a personalized model only exhibits fair use violations in deployment. Here, group (1, 0) experiences an gain once the model is deployment. In contrast, group (0, 1) experiences a fair use violation as a result of sampling error.

Group		Training Data		True Distribution		Model Predictions		Train Performance			True Performance		
$g_1$	$g_2$	$n^+$	$n^-$	$n^+$	$n^-$	$h_0(\mathbf{x})$	$h_g(\mathbf{x}, g)$	$R_g(h_0)$	$R_g(h_g)$	$\Delta_g(h_g, h_0)$	$R_g(h_0)$	$R_g(h_g)$	$\Delta_g(h_g, h_0)$
0	0	20	0	20	0	+	+	0	0	0	0	0	0
1	0	5	25	5	25	+	-	25	5	20	25	5	20
0	1	5	25	30	25	+	-	25	5	20	20	30	-10
1	1	20	0	20	0	+	+	0	0	0	0	0	0
Total		50	50	75	45	+	N/A	50	10	40	45	35	10

**Figure 7:** Label shift produces a fair use violation. Here, we train a linear classifier on a dataset with [one binary feature and one binary group attribute]. As shown, personalization leads to overall improvement reducing aggregate reduce from 50 to 24 and group-specific improvement on the training data. However, not all groups perform equally well in deployment. While groups (0, 1) and (1, 1) see improvements, a violation (red) occurs for group (1, 0) due to the label shift where positive examples are no longer present meanwhile they were the majority in the training data.



GROUP	TEST AUC		INTERVENTIONS		TEST ERROR		INTERVENTION		TEST ECE		INTERVENTIONS	
	$R_g(h_g)$	$\Delta_g$	Assign $h_0$	Assign $h_{dp}$	$R_g(h_g)$	$\Delta_g$	Assign $h_0$	Assign $h_g^{dep}$	$R_g(h_g)$	$\Delta_g$	Assign $h_0$	Assign $h_g^{dep}$
<b><math>g</math></b>	0.463	0.024	0.024	0.334	52.2%	6.8%	6.8%	37.3%	31.6%	2.3%	2.3%	12.3%
female, black	0.846	0.004	0.004	0.004	21.7%	2.0%	2.0%	2.0%	10.2%	1.9%	1.9%	2.1%
female, white	0.860	-0.003	0.000	0.057	25.5%	1.3%	1.3%	14.8%	15.5%	0.9%	0.9%	5.0%
female, other	0.767	-0.001	0.000	0.104	34.0%	-5.2%	0.0%	15.6%	20.1%	-2.0%	0.0%	4.9%
male, black	0.767	0.004	0.004	0.038	29.2%	1.3%	1.3%	3.7%	10.3%	1.2%	1.2%	1.2%
male, white	0.836	-0.002	0.000	0.017	27.9%	-5.0%	0.0%	1.3%	15.4%	-1.6%	0.0%	0.0%
<b>Total</b>	0.800	0.006	-	-	28.3%	0.3%	-	-	4.7%	0.2%	-	-

**Table 3:** Fair use evaluation of a personalized logistic regression model with a one-hot encoding of group attributes for kidney. As shown, personalization can improve overall performance while reduces performance for specific groups (red). This result holds across all performance metrics. In such cases, we can resolve fair use violations and improve the gains from personalization by assigning personalized predictions to each group with multiple models. Here, we show the gains when we assign each group the most accurate predictions from either the personalized model  $h_g$  or a generic classifier  $h_0$ , assign each group the most accurate predictions from the personalized model  $h_g$  or a decoupled classifier  $h^{dep}$ . We highlight cases this intervention led to a gain in green, and cases where it resolved a violation in yellow.

## 512 F Mortality Prediction for Acute Kidney Injury

513 In this section, we evaluate the gains of personalization in model to predict mortality for patients with  
514 acute kidney injury. We use our results to discuss how fair use evaluations as form of auditing [53]  
515 can inform the use of race in clinical prediction models, and describe simple interventions to mitigate  
516 harm.

### 517 F.1 Setup

518 We consider a classification task to predict mortality for patients who receive continuous renal  
519 replacement therapy while in the ICU. The data consists of records for  $n = 2066$  patients from  
520 MIMIC III and IV [38]. Here,  $y_i = +1$  if patient  $i$  dies in the ICU and  $\Pr(y_i = +1) = 51.1\%$ . Each  
521 patient has  $k = 2$  group attributes:  $sex \in \{\text{male, female}\}$  and  $race \in \{\text{white, black, other}\}$   
522 and  $d = 78$  features related to their health, lab tests, length of stay, and potential for organ failure.  
523 We train and evaluate personalized models using the same setup as Section 4.1.

### 524 F.2 Results

525 We show the performance of a personalized logistic regression model with a one-hot encoding in  
526 Table 3, and present results for other model classes in Appendix G. Overall, our findings show that  
527 personalization yields uneven gains at a group level. As in Section 4.2, we observe fair use violations  
528 across performance metrics and model classes. In this case, for example, the gains in error across  
529 range from -5.2% to 6.8%, and two groups experience statistically significant fair use violations:  
530 (male, black) and (male, other).

531 **On the Use of Race** Clinical prediction models include group attributes when there is a “plausible”  
532 causal relationship between group membership and the outcome of interest. These norms have led to  
533 development of widely-used clinical prediction models that use race and ethnicity [25, 71]. Recently,  
534 Vyas et al. [71] discuss how these models can inflict harm and urge physicians to check if “race  
535 correction is based on robust [statistical] evidence.”

536 Our results highlight how fair use evaluation can provide evidence that serves as a barrier to “race  
537 correction” in such cases. Here, checking rationality shows that a race-specific model can reduce  
538 performance for specific groups – e.g., (male, black) and (male, other). Checking envy-  
539 freeness reveals that certain groups expect better performance by misreporting their group membership  
540 – e.g., (male, other) would experience 5.6% gain in test error by reporting any other race.

541 Even in cases where including race can improve performance, we note that race may act as a proxy  
542 for broader social determinants of health. Thus, a model that includes race may act as a “smoke  
543 screen” in that it attributes differences in health outcomes to an immutable factor, and perpetuates  
544 inaction on the root causes of health disparities [57]. Given these drawbacks, the starting point should  
545 be evidence of gain rather than harm.

546 **F.3 Interventions**

547 We use our results to simple interventions that can resolve fair use violations by assigning predictions  
 548 from different models at prediction time. These interventions are admittedly simple, but have the  
 549 benefit of being broadly applicable.

550 **Assigning a Generic Model** We assign groups who are subject to a fair use violation the predictions  
 551 from a generic model  $h_0$ . This intervention is guaranteed to resolve all fair use violations in a way  
 552 that strictly improves performance, and may further reduce the use of personal data in prediction. In  
 553 this case, it resolves all rationality violations (2/3/2 in terms of error/AUC/ECE respectively). We  
 554 also observe a potential to reduce data use: seeing how both (male, black) and (male, other)  
 555 experience a fair use violation in terms of error, we see that we could avoid soliciting race for all  
 556 male patients and reduce test error by 1% (as the loss in accuracy for (white, male) are offset by  
 557 the gain in accuracy for (male, black) and (male, other).

558 **Assigning a Decoupled Model** We assign groups who experience a fair use violation the predic-  
 559 tions from a *decoupled model*  $h_g^{\text{dcp}}$  – i.e., a model fit using only data from their group. While this  
 560 approach may not resolve fair use violations, it can produce surprisingly large gains as decoupling  
 561 effectively personalizes the entire model development pipeline. Our results in Table 3 show the  
 562 potential gains of this intervention across performance metrics. Focusing on error, we see that one can:  
 563 (1) eliminate fair use violations for 2 groups (male, black) and (male, other); (2) greatly improve  
 564 the gains for 1 group, e.g., (female, black) who experience a gain of **37.3%**; and (3) improve  
 565 overall gains by 6.2%. We observe similar effects across other model classes and configurations.

566 **G Supporting Material for Sections 4 & F**

567 In this Appendix, we provide: (i) additional information on the datasets used in Sections 4 and F; (ii)  
 568 results showing the gains of personalization when fitting personalized neural nets and random forests.

569 **G.1 Additional Information on Datasets**

Dataset	$n$	$d$	$\mathcal{G}$	Prediction Task	Reference
apnea	1,152	26	Age $\times$ Sex = {<30, 30 to 60, 60+} $\times$ {Male, Female}	patient has obstructive sleep apnea	Ustun et al. [66]
cardio_eicu	1,341	49	Age $\times$ Sex = {Young, Old} $\times$ {Male, Female}	patient with cardiogenic shock dies	Pollard et al. [60]
cardio_mimic	5,289	49	Age $\times$ Sex = {Young, Old} $\times$ {Male, Female}	patient with cardiogenic shock dies	Johnson et al. [38]
heart	181	26	Age $\times$ Sex = {Young, Old} $\times$ {Male, Female}	patient has heart disease	Detrano et al. [17]
kidney	2066	78	Sex $\times$ Race = {Male, Female} $\times$ {White, Black, Other}	mortality of patient on CRRT	Johnson et al. [38]
mortality	21,139	484	Age $\times$ Sex = {< 30, 30 to 60, 60+} $\times$ {Male, Female}	mortality of patient in ICU	Harutyunyan et al. [34]
saps	7,797	36	Age $\times$ HIV = {≤ 30, 30+} $\times$ {Positive, Negative}	mortality of patient in ICU	Le Gall et al. [48]

**Table 4:** Overview of classification datasets used to train clinical prediction models in Sections 4 and F. We describe the conditions that lead to  $y_i$  under each prediction task. All datasets used are publicly available, have been deidentified, and inspected to ensure that they contain no offensive content. In cases where data access requires consent or approval from the data holders, we have followed the proper procedure to obtain such consent. Datasets based on MIMIC-III [38] (kidney, mortality) and eICU [60] (cardio) are hosted on PhysioNet under the PhysioNet Credentialed Health Data License. The heart dataset is hosted on the UCI ML Repository under an Open Data license. The apnea and saps datasets must be requested from the authors of the papers listed above [48, 66]. We minimally process each dataset to impute the values of missing points (using mean value imputation), and repair class imbalances across intersectional groups (to eliminate “trivial” fair use violations that occur due to class imbalance).

570 **apnea** We use the obstructive sleep apnea (OSA) dataset outlined in Ustun et al. [66]. In this  
 571 dataset, we have a cohort of 1152 patients where 23% have OSA. We use all available features (e.g.  
 572 BMI, comorbordities, age, and sex) and binarize them, resulting in 26 binary features.

573 **cardio\_eicu & cardio\_mimic** Cardiogenic shock is a serious acute condition where the heart  
 574 cannot provide sufficient blood to the vital organs. Using the eICU Collaborative Research Database  
 575 V2.0 [60] and MIMIC-III database [38], we create a cohort of patients who have cardiogenic shock  
 576 during the course of their intensive care unit (ICU) stay. We use an exhaustive set of clinical criteria

577 based on the patient’s labs and vitals (i.e. presence of hypotension and organ hypoperfusion). The goal  
578 is to predict whether a patient with cardiogenic shock will die in hospital. As features, we summarize  
579 (minimums and maximums) relevant labs and vitals (e.g. systolic BP, heart rate, hemoglobin count)  
580 of each patient from the period of time prior to the onset of cardiogenic shock up to 24 hours. This  
581 results in a dataset containing 8,815 patients, 13.5% of whom die in hospital.

582 **heart** We use the Heart dataset from the UCI Machine Learning Repository, where the goal is  
583 to predict the presence of heart disease from clinical features. It consists of 303 patients, 54.5% of  
584 which have heart disease. We use all available features, treating *cp*, *thal*, *ca*, *slope* and *restecg* as  
585 categorical, and all remaining features as continuous.

586 **kidney** Using MIMIC-III and MIMIC-IV [38], we create a cohort of patients who were given  
587 Continuous Renal Replacement Therapy (CRRT) at any point during their ICU stay. For patients with  
588 multiple ICU stays, we select their first one. We define the target as whether the patient dies during  
589 the course of their selected hospital admission. As features, we select the most recent instances of  
590 relevant lab measurements (e.g. sodium, potassium, creatinine) prior to the CRRT start time, along  
591 with the patient’s age, the number of hours they have been in ICU when CRRT was administered,  
592 and their Sequential Organ Failure Assessment (SOFA) score at admission. We treat all variables as  
593 continuous with the exception of the SOFA score, which we treat as ordinal. This results in a dataset  
594 of 1,722 CRRT patients, 51.1% of which die in-hospital. We define protected groups based on the  
595 patient’s sex and self-reported race and ethnicity.

596 **mortality** We follow the cohort creation steps outlined by Harutyunyan et al. [34] for their  
597 in-hospital mortality prediction task. We select the first ICU stay longer than 48 hours of patients  
598 in MIMIC-III [38], and aim to predict whether they will die in-hospital during their corresponding  
599 hospital admission. As features, we bin the time-series lab and vital measurements provided by  
600 Harutyunyan et al. [34] into four 12-hour time-bins, and compute the mean in each time-bin. We  
601 additionally include the patient’s age and sex as features. This results in a cohort of 21,139 patients,  
602 13.2% of whom die in hospital.

603 **saps** The Simplified Acute Physiology Score II (SAPS II) is a risk score that was developed for  
604 predicting mortality in the ICU [48]. This study was conducted in 137 medical centers across 12  
605 countries contains 7,797 patients. For each patient we have access to demographics, comorbidities,  
606 and vitals which are used to predict the risk of mortality in the ICU. For group attributes we use age  
607 and HIV status. The percentage of patients in the dataset who experience mortality is 21.8%.

## 608 **G.2 Results for Neural Nets & Random Forests**

609 In this Appendix, we present tables that summarize the gains of personalization for neural networks  
610 and random forests. The following tables are analogous to Table 1, except that they also include  
611 results for the *kidney* dataset in Section F.

### 612 **G.2.1 Neural Nets**

613 For our neural network models we trained them with two hidden layers of size 5 and 2 and learning  
614 rate of  $1^{-3}$ . Additionally, we applied Platt scaling [59] the outputs of the neural network model to  
615 ensure that they were calibrated. We note similar findings described in Sections 4.2 and Section F for  
616 neural network models. For example, when looking at test error on *cardio\_eicu* we are able to  
617 eliminate all fair use violations by decoupling models. Additionally, across datasets we are able to  
618 identify statistically significant fair use violations and gains as noted by the gains and violations rows.  
619

Dataset	Metrics	Test AUC			Test ECE				Test Error		
		1Hot	All	DCP	1Hot	All	DCP	1Hot	All	DCP	
apnea	Personalized	0.705	0.524	0.622	6.3%	2.5%	5.3%	36.7%	50.6%	41.5%	
	Gain	-0.012	-0.193	-0.095	-0.7%	3.2%	0.4%	-3.3%	-17.2%	-8.1%	
	Best/Worst Gain	0.114 / -0.051	0.029 / -0.501	-0.068 / -0.328	10.9% / -8.2%	24.0% / 1.5%	9.8% / -5.7%	8.4% / -5.0%	7.1% / -43.5%	-2.2% / -50.5%	
	Rat. Gains/VIols	3/3	5/5	6/6	3/3	5/5	3/3	1/2	1/1	0/0	
cardio_eicu	Personalized	0.739	0.738	0.687	4.5%	5.5%	5.4%	31.5%	31.8%	36.6%	
	Gain	0.001	-0.001	-0.051	2.3%	1.4%	1.5%	1.6%	1.3%	-3.5%	
	Best/Worst Gain	0.067 / -0.003	0.029 / -0.012	0.007 / -0.090	2.6% / -1.2%	2.4% / -1.9%	4.9% / -3.0%	8.4% / -0.5%	5.5% / -1.3%	0.1% / -10.2%	
	Rat. Gains/VIols	0/0	1/1	3/3	3/3	3/3	2/2	2/3	2/3	0/0	
cardio_mimic	Personalized	0.849	0.849	0.836	3.1%	4.7%	3.3%	23.7%	24.0%	23.9%	
	Gain	0.004	0.004	-0.009	1.1%	-0.4%	1.0%	0.6%	0.2%	0.4%	
	Best/Worst Gain	0.018 / -0.005	0.012 / -0.000	0.004 / -0.014	2.1% / -0.4%	1.4% / -2.3%	2.5% / -0.3%	2.0% / -1.1%	2.3% / -2.4%	1.3% / -1.4%	
	Rat. Gains/VIols	1/1	0/0	2/2	2/2	2/2	3/3	3/3	2/2	2/2	
heart	Personalized	0.457	0.736	0.554	22.7%	17.2%	18.1%	52.6%	27.6%	38.2%	
	Gain	-0.090	0.189	0.007	-9.1%	-3.6%	-4.5%	-1.3%	23.7%	13.2%	
	Best/Worst Gain	0.061 / -0.392	0.317 / 0.023	0.257 / -0.023	4.8% / -29.8%	9.8% / -9.7%	6.2% / -14.8%	1.6% / -9.2%	38.0% / 4.6%	28.1% / 7.1%	
	Rat. Gains/VIols	2/2	0/0	2/1	1/1	1/1	2/2	0/2	4/4	3/4	
kidney	Personalized	0.774	0.774	0.762	6.0%	6.2%	7.3%	29.2%	31.0%	30.9%	
	Gain	0.003	0.004	-0.009	-0.1%	-0.4%	-1.4%	-2.1%	-3.8%	-3.7%	
	Best/Worst Gain	0.039 / -0.057	0.026 / -0.095	0.033 / -0.152	2.8% / -1.6%	3.7% / -2.5%	0.8% / -5.4%	-0.6% / -7.5%	4.7% / -5.4%	-1.5% / -18.9%	
	Rat. Gains/VIols	2/2	3/3	4/4	2/2	2/2	1/1	0/0	1/1	0/0	
mortality	Personalized	0.870	0.869	0.895	2.8%	4.3%	3.0%	20.9%	21.5%	17.7%	
	Gain	-0.004	-0.004	0.022	0.6%	-0.9%	0.5%	-0.4%	-1.0%	2.8%	
	Best/Worst Gain	0.025 / -0.019	-0.001 / -0.015	0.039 / 0.005	2.7% / -1.7%	0.5% / -1.2%	8.0% / 0.1%	5.1% / -2.2%	-0.3% / -2.3%	12.6% / 0.1%	
	Rat. Gains/VIols	3/3	5/5	0/0	3/3	2/2	5/5	3/3	0/0	6/6	
saps	Personalized	0.157	0.872	0.758	37.8%	7.8%	31.5%	63.4%	21.7%	48.9%	
	Gain	-0.037	0.678	0.565	7.5%	37.5%	13.9%	-1.8%	39.9%	12.7%	
	Best/Worst Gain	0.101 / -0.041	0.745 / 0.657	0.743 / -0.273	27.1% / 1.5%	43.2% / -3.5%	49.9% / 6.4%	0.0% / -5.8%	53.9% / 1.4%	22.0% / 0.0%	
	Rat. Gains/VIols	3/2	0/0	1/1	4/4	3/3	4/4	0/1	3/4	3/4	
apnea	Personalized	0.705	0.524	0.622	6.3%	2.5%	5.3%	36.7%	50.6%	41.5%	
	Gain	-0.012	-0.193	-0.095	-0.7%	3.2%	0.4%	-3.3%	-17.2%	-8.1%	
	Best/Worst Gain	0.114 / -0.051	0.029 / -0.501	-0.068 / -0.328	10.9% / -8.2%	24.0% / 1.5%	9.8% / -5.7%	8.4% / -5.0%	7.1% / -43.5%	-2.2% / -50.5%	
	Rat. Gains/VIols	3/3	5/5	6/6	3/3	5/5	3/3	1/2	1/1	0/0	

**Table 5:** Performance of personalized neural network models on all datasets. We show the gains of personalization in terms of test AUC, ECE, and error. We report: model performance at the population level, the overall gain of personalization, the range of gains over  $m$  intersectional groups, and the number of rationality and envy-freeness gains/violations (evaluated using a bootstrap hypothesis test at a 10% significance level).

## 620 G.2.2 Random Forests

621 For our random forest models, we trained each with the following hyperparameters: 100 estimators,  
622 max depth of 20, minimum samples per split is 5, and minimum number of samples in each leaf is 2.  
623 For random forests, we expect that these models will perform well when optimizing error but will  
624 not necessarily have high AUC or be well calibrated (i.e. low ECE). We note this in the Table below.  
625 For example, using an intersectional encoding with random forests is effective in minimizing fair  
626 use violations on error across multiple datasets (e.g. `apnea`, `kidney`). As noted with both logistic  
627 regression and neural networks, we are able to reliably identify statistically significant violations.

Dataset	Metrics	Test AUC		Test ECE		Test Error	
		1Hot	All	1Hot	All	1Hot	All
apnea	Personalized	0.757	0.759	7.7%	7.1%	30.5%	31.2%
	Gain	0.002	0.004	-0.4%	0.6%	0.8%	-0.5%
	Best/Worst Gain	0.064 / -0.001	0.020 / -0.009	4.4% / -2.7%	6.8% / -0.3%	9.8% / -2.8%	4.3% / -1.5%
	Rat. Gains/Viols	1/1	2/2	2/2	3/3	5/5	2/4
	EF Gains/Viols	4/0	4/2	4/5	3/3	6/6	6/6
cardio_eicu	Personalized	0.764	0.772	7.8%	8.7%	30.8%	30.2%
	Gain	0.001	-0.000	-1.3%	-0.7%	1.0%	0.4%
	Best/Worst Gain	0.009 / -0.022	0.014 / -0.028	3.7% / -0.8%	1.0% / -3.5%	4.9% / -1.6%	1.4% / -1.8%
	Rat. Gains/Viols	1/1	2/2	2/2	1/1	3/3	1/3
	EF Gains/Viols	1/1	3/3	3/3	3/3	4/4	4/4
cardio_mimic	Personalized	0.847	0.847	9.2%	9.7%	24.0%	24.3%
	Gain	-0.003	0.001	0.4%	-0.4%	-0.2%	-0.3%
	Best/Worst Gain	-0.001 / -0.004	0.002 / -0.001	1.2% / 0.2%	0.3% / -0.9%	0.8% / -1.1%	0.3% / -1.4%
	Rat. Gains/Viols	4/4	2/2	4/4	1/1	1/1	1/1
	EF Gains/Viols	2/2	2/1	1/1	3/3	4/4	4/4
heart	Personalized	0.897	0.896	12.0%	14.4%	17.1%	22.4%
	Gain	-0.006	-0.000	4.6%	-2.7%	-2.6%	-2.6%
	Best/Worst Gain	0.006 / -0.025	0.000 / -0.026	5.5% / -1.8%	9.3% / -5.1%	9.6% / -10.8%	5.6% / -10.7%
	Rat. Gains/Viols	3/1	4/1	2/2	1/1	1/2	0/2
	EF Gains/Viols	4/0	2/0	2/2	2/2	4/4	4/4
kidney	Personalized	0.775	0.778	8.8%	9.0%	29.2%	29.1%
	Gain	0.001	0.003	-0.7%	-1.1%	1.2%	1.0%
	Best/Worst Gain	0.010 / -0.017	0.009 / -0.019	2.0% / -1.9%	1.2% / -3.8%	5.3% / -0.9%	2.0% / -3.1%
	Rat. Gains/Viols	3/2	3/3	1/1	1/1	4/5	2/5
	EF Gains/Viols	3/0	3/2	4/6	3/3	6/6	6/6
mortality	Personalized	0.806	0.806	10.9%	10.8%	27.2%	27.1%
	Gain	0.002	-0.001	-0.6%	-0.0%	0.3%	-0.1%
	Best/Worst Gain	0.005 / 0.001	0.012 / -0.004	1.4% / -1.2%	1.5% / -3.1%	0.9% / -0.5%	0.7% / -1.8%
	Rat. Gains/Viols	0/0	2/2	1/1	2/2	3/3	3/4
	EF Gains/Viols	6/0	3/1	3/5	2/6	6/6	6/6
saps	Personalized	0.879	0.878	4.6%	4.9%	20.1%	20.0%
	Gain	-0.002	-0.002	0.0%	0.1%	-0.4%	-0.4%
	Best/Worst Gain	0.000 / -0.050	0.050 / -0.002	11.2% / -1.6%	0.2% / -3.5%	0.0% / -10.0%	0.2% / -5.4%
	Rat. Gains/Viols	3/2	2/1	2/2	2/2	0/1	0/2
	EF Gains/Viols	3/1	4/2	4/4	4/4	4/4	4/4

**Table 6:** Performance of personalized random forest models on all datasets. We show the gains of personalization in terms of test AUC, ECE, and error. We report: model performance at the population level, the overall gain of personalization, the range of gains over  $m$  intersectional groups, and the number of rationality and envy-freeness gains/violations (evaluated using a bootstrap hypothesis test at a 10% significance level).